Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Farallon Capital Management LLC

Farallon Capital Management LLC boosted its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 1.8% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,840,773 shares of the company’s stock after acquiring an additional 101,800 shares during the quarter. Protagonist Therapeutics comprises approximately 1.0% of Farallon Capital Management LLC’s portfolio, making the stock its 29th biggest holding. Farallon Capital Management LLC owned about 9.92% of Protagonist Therapeutics worth $202,383,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Superstring Capital Management LP purchased a new position in shares of Protagonist Therapeutics in the 4th quarter valued at about $8,694,000. Renaissance Technologies LLC boosted its stake in shares of Protagonist Therapeutics by 813.4% during the 2nd quarter. Renaissance Technologies LLC now owns 297,467 shares of the company’s stock worth $10,307,000 after acquiring an additional 264,900 shares in the last quarter. ADAR1 Capital Management LLC purchased a new stake in shares of Protagonist Therapeutics during the 4th quarter worth approximately $4,606,000. Kynam Capital Management LP grew its holdings in shares of Protagonist Therapeutics by 10.2% in the 4th quarter. Kynam Capital Management LP now owns 2,004,875 shares of the company’s stock worth $45,972,000 after acquiring an additional 186,218 shares during the period. Finally, Privium Fund Management B.V. purchased a new position in Protagonist Therapeutics in the 1st quarter valued at approximately $3,299,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Performance

Shares of NASDAQ PTGX opened at $46.15 on Tuesday. The firm has a market cap of $2.71 billion, a P/E ratio of 18.91 and a beta of 2.17. Protagonist Therapeutics, Inc. has a 1 year low of $13.72 and a 1 year high of $48.00. The firm’s 50 day moving average price is $41.02 and its 200 day moving average price is $33.85.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.50). The business had revenue of $4.17 million for the quarter, compared to analyst estimates of $40.00 million. As a group, equities analysts predict that Protagonist Therapeutics, Inc. will post 2.31 EPS for the current year.

Insider Buying and Selling at Protagonist Therapeutics

In other news, Director William D. Waddill sold 8,000 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total transaction of $360,000.00. Following the transaction, the director now directly owns 12,000 shares in the company, valued at approximately $540,000. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CFO Asif Ali sold 14,203 shares of the stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $44.49, for a total value of $631,891.47. Following the completion of the sale, the chief financial officer now owns 34,960 shares in the company, valued at $1,555,370.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director William D. Waddill sold 8,000 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total value of $360,000.00. Following the sale, the director now owns 12,000 shares in the company, valued at $540,000. The disclosure for this sale can be found here. Insiders sold 30,203 shares of company stock worth $1,311,891 in the last 90 days. 5.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on PTGX shares. JMP Securities lowered their target price on Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 7th. JPMorgan Chase & Co. increased their price objective on shares of Protagonist Therapeutics from $39.00 to $48.00 and gave the company an “overweight” rating in a research note on Thursday, July 25th. StockNews.com upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. BTIG Research increased their price target on shares of Protagonist Therapeutics from $41.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Finally, Truist Financial assumed coverage on Protagonist Therapeutics in a research report on Monday, September 9th. They set a “buy” rating and a $60.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $47.33.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.